ArticleActa parasitologica2025
Absence of Artemisinin Resistance-Associated Mutations in the Plasmodium Falciparum Kelch 13 (K13) Propeller Domain Gene Following Widespread Use of Artemisinin-Based Combination Therapy in Iran.
Article in Acta parasitologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeContinuous surveillance of Plasmodium falciparum Kelch 13 (pfk13) mutations associated with artemisinin resistance is essential for monitoring the emergence of drug-resistant parasites in malaria-endemic regions. Herein, we have assessed the prevalence of point mutations in the pfk13 gene linked to artemisinin resistance in Iranian P. falciparum isolates, 18 years following the nationwide introduction of artemisinin-based combination therapies (ACTs).
methodsA total of 60 finger-prick blood samples were obtained from Iranian patients with symptomatic, uncomplicated P. falciparum malaria during the period of 2022 to 2023. A nested polymerase chain reaction (PCR) assay was employed to verify infections by amplifying the 18 S small subunit ribosomal RNA (18 S ssrRNA) gene. Nested PCR was utilized to amplify the pfk13 gene, followed by sequencing of the amplicons to identify both previously reported and novel mutations.
resultsOf the successfully sequenced samples (n = 50), 98% (49/50) carried the wild-type allele. One sample harbored a novel nonsynonymous mutation, R513C, corresponding to a C1537T nucleotide change.
conclusionNo validated pfk13 mutations indicative of artemisinin resistance were detected in the study population. These findings suggest that artemisinin remains effective for treating P. falciparum malaria in this region. Continued molecular surveillance is warranted to ensure early detection of emerging resistance.
Indexed as
Identifiers
41400738What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.